A community-based model of rapid autopsy in end-stage cancer patients

K Alsop, H Thorne, S Sandhu, A Hamilton… - Nature …, 2016 - nature.com
K Alsop, H Thorne, S Sandhu, A Hamilton, C Mintoff, E Christie, O Spruyt, S Williams
Nature biotechnology, 2016nature.com
To the Editor: Systematic genomic studies, including the Cancer Genome Atlas (TCGA) 1
and the International Cancer Genome Consortium (ICGC) 2, have provided an
unprecedented catalog of driver mutations in human cancer. However, these studies use
mainly primary, pre-treatment tumor material obtained at surgery with curative intent. There
is an urgent need to identify and characterize resistance mechanisms to understand how
cancers can evade even the best medical efforts and kill patients; therefore, access to end …
To the Editor: Systematic genomic studies, including the Cancer Genome Atlas (TCGA) 1 and the International Cancer Genome Consortium (ICGC) 2, have provided an unprecedented catalog of driver mutations in human cancer. However, these studies use mainly primary, pre-treatment tumor material obtained at surgery with curative intent. There is an urgent need to identify and characterize resistance mechanisms to understand how cancers can evade even the best medical efforts and kill patients; therefore, access to end-stage disease is important. Solid cancers show considerable spatial3, temporal4, 5 and genomic heterogeneity at diagnosis. Selective pressure and mutagenic impact of treatment6 drives intra-patient evolution of cancer cell populations4, 7. Understanding acquired resistance requires access to paired pre-and post-treatment samples4, 7; however, curative surgery is typically confined to patients with locoregional disease, and opportunities for tumor sampling in advanced disseminated disease are limited. Here, we describe Cancer Tissue Collection After Death (CASCADE), an autopsy program that overcomes logistical challenges to enable collection of samples at end stage for research in melanoma and breast, ovarian and prostate cancers. For the CASCADE study, we aimed to recruit cancer patients close to the end of life, including those outside the minority of patients who die in hospitals. To preserve tissue integrity, autopsies must commence within a few hours of death, requiring access to around-the-clock services. Intervention in the emotionally charged end-of-life environment must be managed in an ethical manner and to a high standard. Finally, we aimed for the study to be highly cost-effective. We believe our approach to meeting these challenges is applicable to researchers in other large urban centers. Here we summarize the main steps in CASCADE’s operating protocol and our experiences from the initial 3 years and 30 autopsies performed (Fig. 1). Information about institutional review board approvals (including a detailed patient informationand-consent form), the autopsy procedure and certain laboratory processes is given in Supplementary Methods and
nature.com